This report presents the results of a qualitative study into the socio-ethical benefits and socio-ethical risks of using digital twins in
healthcare based on the outcome of 23 interviews and 1 expert workshop.
Positioning In Silico Medicine as a computationally-intensive science
In this post, Prof Marco Viceconti calls to arms the in silico medicine community in respect to the scalability grand challenge and its HPC needs.
Stakeholder workshop on the Human Digital Twin organized by the European Commission
On 6 November 2020, a stakeholder workshop on the Human Digital Twin (HDT) was organised by the European Commission.
FDA’s driver of in silico medicine, Tina Morrison, promoted to Director of Regulatory Science and Innovation at FDA
Our long-term collaborator and in silico advocate at FDA, Tina Morrison, has been promoted to Director of Regulatory Science and Innovation